Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
116,932,531
-
Total 13F shares
-
104,076,200
-
Share change
-
-398,776
-
Total reported value
-
$935,658,582
-
Put/Call ratio
-
68%
-
Price per share
-
$8.99
-
Number of holders
-
286
-
Value change
-
-$52,665,542
-
Number of buys
-
151
-
Number of sells
-
132
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2025
As of 31 Dec 2025,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
286 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
104,076,200 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock, Inc., STATE STREET CORP, D. E. Shaw & Co., Inc., REGENERON PHARMACEUTICALS, INC., TWO SIGMA INVESTMENTS, LP, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, and MORGAN STANLEY.
This page lists
286
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.